ST3 beta-galactoside alpha-2,3-sialyltransferase 1 (ST3Gal1) synthesis of Siglec ligands mediates anti-tumour immunity in prostate cancer

ST3 beta-galactoside alpha-2,3-sialyltransferase 1 (ST3Gal1) synthesis of Siglec ligands mediates anti-tumour immunity in prostate cancer

Abstract Immune checkpoint blockade has yet to produce robust anti-cancer responses for prostate cancer. Sialyltransferases have been shown across several solid tumours, including breast, melanoma, colorectal and prostate to promote immune suppression by synthesising sialoglycans, which act as ligan...

Full description

Bibliographic Details
Main Authors: Rebecca Garnham, Daniel Geh, Ryan Nelson, Erik Ramon-Gil, Laura Wilson, Edward N. Schmidt, Laura Walker, Beth Adamson, Adriana Buskin, Anastasia C. Hepburn, Kirsty Hodgson, Hannah Kendall, Fiona M. Frame, Norman Maitland, Kelly Coffey, Douglas W. Strand, Craig N. Robson, David J. Elliott, Rakesh Heer, Matthew Macauley, Jennifer Munkley, Luke Gaughan, Jack Leslie, Emma Scott
Format: Article
Language:English
Published: Nature Portfolio 2024-03-01
Series:Communications Biology
Online Access:https://doi.org/10.1038/s42003-024-05924-0

Internet

https://doi.org/10.1038/s42003-024-05924-0

Similar Items